{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:18Z","timestamp":1790742018386,"version":"4.1.0"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tyrosine kinase inhibitors (TKI) have revolutionized chronic myelogenous leukemia (CML) management. Disease eradication, however, is hampered by innate resistance of leukemia-initiating cells (LIC) to TKI-induced killing, which also provides the basis for subsequent emergence of TKI-resistant mutants. We report that EZH2, the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), is overexpressed in CML LICs and required for colony formation and survival and cell-cycle progression of CML cell lines. A critical role for EZH2 is supported by genetic studies in a mouse CML model. Inactivation of Ezh2 in conventional conditional mice and through CRISPR\/Cas9-mediated gene editing prevents initiation and maintenance of disease and survival of LICs, irrespective of BCR\u2013ABL1 mutational status, and extends survival. Expression of the EZH2 homolog EZH1 is reduced in EZH2-deficient CML LICs, creating a scenario resembling complete loss of PRC2. EZH2 dependence of CML LICs raises prospects for improved therapy of TKI-resistant CML and\/or eradication of disease by addition of EZH2 inhibitors.<\/jats:p>\n                  <jats:p>Significance: This work defines EZH2 as a selective vulnerability for CML cells and their LICs, regardless of BCR\u2013ABL1 mutational status. Our findings provide an experimental rationale for improving disease eradication through judicious use of EZH2 inhibitors within the context of standard-of-care TKI therapy. Cancer Discov; 6(11); 1237\u201347. \u00a92016 AACR.<\/jats:p>\n                  <jats:p>See related article by Scott et al., p. 1248.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 1197<\/jats:p>","DOI":"10.1158\/2159-8290.cd-15-1439","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T22:23:50Z","timestamp":1473891830000},"page":"1237-1247","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Chronic Myelogenous Leukemia\u2013 Initiating Cells Require Polycomb Group Protein EZH2"],"prefix":"10.1158","volume":"6","author":[{"given":"Huafeng","family":"Xie","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Peng","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Huang","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Heath, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin E.","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woojin","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elenoe C.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qi","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cheloni","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts."},{"name":"5Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio,\u201d University of Florence, Florence, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha P.","family":"Das","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoguang","family":"Li","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Bradner","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"6Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Orkin","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"7Howard Hughes Medical Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"key":"2022060700345330200_bib1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"2022060700345330200_bib2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/330386a0","article-title":"A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia","volume":"330","author":"Fainstein","year":"1987","journal-title":"Nature"},{"key":"2022060700345330200_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0033-1343483","article-title":"TK inhibitor treatment disrupts growth hormone axis: Clinical observations in children with CML and experimental data from a juvenile animal model","volume":"225","author":"Ulmer","year":"2013","journal-title":"Klin Padiatr"},{"key":"2022060700345330200_bib4","first-page":"1111","article-title":"Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia","volume":"6","author":"Price","year":"2013","journal-title":"Onco Targets Ther"},{"key":"2022060700345330200_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/asheducation-2013.1.189","article-title":"Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: Tyrosine-kinase inhibitor combinations and beyond","volume":"2013","author":"Ahmed","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2022060700345330200_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"2022060700345330200_bib7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060700345330200_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"2022060700345330200_bib9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"2022060700345330200_bib10","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060700345330200_bib11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/sj.bjc.6602531","article-title":"Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma","volume":"92","author":"Sudo","year":"2005","journal-title":"Br J Cancer"},{"key":"2022060700345330200_bib12","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-10-2156","article-title":"Aberrations of EZH2 in cancer","volume":"17","author":"Chase","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022060700345330200_bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0002-9440(10)64583-X","article-title":"Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease","volume":"157","author":"Raaphorst","year":"2000","journal-title":"Am J Pathol"},{"key":"2022060700345330200_bib14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"2022060700345330200_bib15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"key":"2022060700345330200_bib16","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"2022060700345330200_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1101\/gad.186411.111","article-title":"A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia","volume":"26","author":"Simon","year":"2012","journal-title":"Genes Dev"},{"key":"2022060700345330200_bib18","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1073\/pnas.1202258109","article-title":"Polycomb repressive complex 2 is required for MLL-AF9 leukemia","volume":"109","author":"Neff","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060700345330200_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"2022060700345330200_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.stem.2013.10.001","article-title":"Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner","volume":"14","author":"Xie","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2022060700345330200_bib21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-05-501072","article-title":"Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile","volume":"122","author":"Cramer-Morales","year":"2013","journal-title":"Blood"},{"key":"2022060700345330200_bib22","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060700345330200_bib23","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"2022060700345330200_bib24","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060700345330200_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"2022060700345330200_bib26","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"2022060700345330200_bib27","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1035902","article-title":"Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein","volume":"16","author":"Kuzmichev","year":"2002","journal-title":"Genes Dev"},{"key":"2022060700345330200_bib28","doi-asserted-by":"crossref","first-page":"27757","DOI":"10.1074\/jbc.M804442200","article-title":"Dominant alleles identify SET domain residues required for histone methyltransferase of Polycomb repressive complex 2","volume":"283","author":"Joshi","year":"2008","journal-title":"J Biol Chem"},{"key":"2022060700345330200_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"2022060700345330200_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","article-title":"Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia","volume":"125","author":"Xu","year":"2015","journal-title":"Blood"},{"key":"2022060700345330200_bib31","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem Biol"},{"key":"2022060700345330200_bib32","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-0164","article-title":"Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer","author":"Zhang","year":"2016  16","journal-title":"Cancer Discov"},{"key":"2022060700345330200_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1097-2765(01)00284-2","article-title":"p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis","volume":"8","author":"Okamura","year":"2001","journal-title":"Mol Cell"},{"key":"2022060700345330200_bib34","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/onc.2008.450","article-title":"Loss of PHLPP expression in colon cancer: Role in proliferation and tumorigenesis","volume":"28","author":"Liu","year":"2009","journal-title":"Oncogene"},{"key":"2022060700345330200_bib35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng0794-440","article-title":"Epigenetic lesions at the H19 locus in Wilms' tumour patients","volume":"7","author":"Moulton","year":"1994","journal-title":"Nat Genet"},{"key":"2022060700345330200_bib36","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1101\/gad.8.24.2939","article-title":"Growth suppression by p18, a p16INK4\/MTS1- and p14INK4B\/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function","volume":"8","author":"Guan","year":"1994","journal-title":"Genes Dev"},{"key":"2022060700345330200_bib37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nbt.3235","article-title":"Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains","volume":"33","author":"Shi","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2022060700345330200_bib38","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2022060700345330200_bib39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"2022060700345330200_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"2022060700345330200_bib41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat Med"},{"key":"2022060700345330200_bib42","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"key":"2022060700345330200_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-213X-1-4","article-title":"Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus","volume":"1","author":"Srinivas","year":"2001","journal-title":"BMC Dev Biol"},{"key":"2022060700345330200_bib44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol Cell"},{"key":"2022060700345330200_bib45","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/6\/11\/1237\/1823836\/1237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/6\/11\/1237\/1823836\/1237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:35:35Z","timestamp":1654547735000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/6\/11\/1237\/5666\/Chronic-Myelogenous-Leukemia-Initiating-Cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-15-1439","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22531218.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531200.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531215.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531209.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531203.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531206","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531206.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531203","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531200","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531212.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531221.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546381","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546381.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,1]]}}}